Information updates

Updated ASCIA COVID-19 vaccination FAQ

ASCIA Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Frequently Asked Questions (FAQ) has been updated to include approval of a new vaccine (Novavax) in Australia and updated advice from the Australian Technical Advisory Group on Immunisation (ATAGI) regarding co-administration of influenza vaccines:

  • Novavax/Biocelect Nuvaxovid spike protein based COVID-19 vaccine was approved in Australia in January 2022, for adults 18 years and over. It is expected to be available from late February 2022.
  • ATAGI now recommends that influenza vaccines can be co-administered with COVID-19 vaccines. Subject to availability of influenza vaccines, an ideal time to vaccinate could be on the same day as a COVID-19 booster vaccine. This updated advice was issued by ATAGI in December 2021, to coincide with borders reopening and greater population movement and an expected resurgence of influenza activity in 2022, outside of the usual influenza season. 

    Previously the preferred minimum interval between a dose of seasonal flu vaccine and a dose of a COVID-19 vaccine was seven days. This was to avoid confusion about the cause of side effects or allergic reactions, if they occur in response to the COVID-19 vaccine or the influenza vaccine. 

Futher information:

https://www.allergy.org.au/patients/ascia-covid-19-vaccination-faq

https://www.health.gov.au/news/atagi-statement-on-the-use-of-novavax-covid-19-vaccine-nuvaxovid

https://www.health.gov.au/news/updated-atagi-advice-on-the-administration-of-seasonal-influenza-vaccines-in-2021-december-2021 

This news item was issued on 9 February 2022 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.

 

 

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.